Kopp Investment Advisors LLC cut its position in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) by 9.4% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 3,905 shares of the specialty pharmaceutical company’s stock after selling 405 shares during the period. Kopp Investment Advisors LLC’s holdings in Eagle Pharmaceuticals were worth $310,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. State Board of Administration of Florida Retirement System boosted its position in Eagle Pharmaceuticals by 2.9% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 5,305 shares of the specialty pharmaceutical company’s stock worth $421,000 after buying an additional 150 shares during the last quarter. New York State Teachers Retirement System boosted its position in Eagle Pharmaceuticals by 2.0% in the fourth quarter. New York State Teachers Retirement System now owns 9,957 shares of the specialty pharmaceutical company’s stock worth $790,000 after buying an additional 200 shares during the last quarter. Comerica Bank boosted its position in Eagle Pharmaceuticals by 5.2% in the fourth quarter. Comerica Bank now owns 8,445 shares of the specialty pharmaceutical company’s stock worth $585,000 after buying an additional 415 shares during the last quarter. Royal Bank of Canada boosted its position in Eagle Pharmaceuticals by 3.5% in the second quarter. Royal Bank of Canada now owns 12,351 shares of the specialty pharmaceutical company’s stock worth $479,000 after buying an additional 417 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. boosted its position in Eagle Pharmaceuticals by 1.7% in the second quarter. Schwab Charles Investment Management Inc. now owns 30,642 shares of the specialty pharmaceutical company’s stock worth $1,189,000 after buying an additional 510 shares during the last quarter.

Institutional Ownership by Quarter for Eagle Pharmaceuticals (NASDAQ:EGRX)

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) traded down 0.04% during mid-day trading on Thursday, hitting $73.27. 241,964 shares of the company’s stock traded hands. Eagle Pharmaceuticals, Inc. has a one year low of $33.02 and a one year high of $87.78. The firm’s 50-day moving average price is $70.68 and its 200-day moving average price is $68.16. The stock has a market cap of $1.13 billion, a PE ratio of 47.70 and a beta of 1.54.

“Eagle Pharmaceuticals, Inc. (EGRX) Shares Sold by Kopp Investment Advisors LLC” was originally published by Watch List News and is owned by of Watch List News. If you are viewing this report on another publication, it was stolen and reposted in violation of United States & international copyright legislation. The correct version of this report can be accessed at http://www.watchlistnews.com/eagle-pharmaceuticals-inc-egrx-shares-sold-by-kopp-investment-advisors-llc/1121251.html.

A number of analysts recently weighed in on the stock. Zacks Investment Research lowered shares of Eagle Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Monday, January 16th. William Blair upped their price objective on shares of Eagle Pharmaceuticals from $83.00 to $97.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 2nd. RBC Capital Markets reaffirmed an “outperform” rating and issued a $93.00 price objective on shares of Eagle Pharmaceuticals in a research note on Monday, November 14th. Mizuho raised shares of Eagle Pharmaceuticals from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $62.00 to $78.00 in a research note on Thursday, November 3rd. Finally, Royal Bank Of Canada upped their price objective on shares of Eagle Pharmaceuticals from $80.00 to $93.00 and gave the stock an “outperform” rating in a research note on Thursday, November 3rd. Two analysts have rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $85.83.

In related news, Director Sander A. Flaum sold 5,000 shares of the firm’s stock in a transaction dated Monday, November 28th. The stock was sold at an average price of $78.66, for a total transaction of $393,300.00. Following the completion of the sale, the director now directly owns 11,374 shares of the company’s stock, valued at approximately $894,678.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Proquest Investments Iv, L.P. sold 65,114 shares of the firm’s stock in a transaction dated Wednesday, January 4th. The stock was sold at an average price of $85.16, for a total value of $5,545,108.24. The disclosure for this sale can be found here. In the last quarter, insiders have sold 80,114 shares of company stock worth $6,688,508. Insiders own 18.80% of the company’s stock.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes EP-1101 (argatroban); Ryanodex (dantrolene sodium); docetaxel injection, non-alcohol formulation (Non-Alcohol Docetaxel Injection); diclofenac-misoprostol; EP-3101 (Bendamustine Hydrochloride Injection, ready-to-dilute (RTD) concentrate solution), and EP-3102 (rapidly infused bendamustine RTD) (EP-3102 Bendeka).

5 Day Chart for NASDAQ:EGRX

Want to see what other hedge funds are holding EGRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX).

Receive News & Ratings for Eagle Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.